Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
CONCLUSION: This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.PMID:38590236 | DOI:10.1080/13696998.2024.2340932 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 9, 2024 Category: Health Management Authors: Karissa Johnston Lauren C Powell Evan Popoff Gil J L'Italien Robert Pawinski Aideen Ahern Sam Large Thang Tran Aaron Jenkins Source Type: research
Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States
Conclusions: In patients with severe/extreme NAO, with NVC as the primary or major contributor, introducing TCRF with ITR as a treatment option demonstrates the potential for significant cost savings over functional rhinoplasty with septoplasty and ITR.PMID:38581156 | DOI:10.1080/13696998.2024.2340385 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 6, 2024 Category: Health Management Authors: Michael Yong Desiree Hollemon Julie Baxter Alex Hirst Sam Bryning Aimee Fox Greg Smith Robert Hughes Giulia Brandolini Scott Wolf Randall Ow Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study
CONCLUSIONS: ICD therapy compared to no ICD therapy is cost-effective for the 1.5PP patients in China.PMID:38566556 | DOI:10.1080/13696998.2024.2333187 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 3, 2024 Category: Health Management Authors: Hui Sun Xin Liu Jin Fu Yin Song Xiaoxiao Qin Haiyin Wang Source Type: research
Addendum
J Med Econ. 2024 Jan-Dec;27(1):518. doi: 10.1080/13696998.2024.2336778. Epub 2024 Apr 2.NO ABSTRACTPMID:38564340 | DOI:10.1080/13696998.2024.2336778 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 2, 2024 Category: Health Management Source Type: research
Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study
Conclusion: EQ-5D-5L is a valid questionnaire to measure health-related quality of life and estimate utility values among HFrEF patients in Malaysia. The Malay and English versions of EQ-5D-5L appear equivalent for clinical and economic assessments.PMID:38557412 | DOI:10.1080/13696998.2024.2337563 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 1, 2024 Category: Health Management Authors: WaiChee Kuan Kok Han Chee Sazzli Kasim Ka Keat Lim Juman Abdulelah Dujaili Kenneth Kwing-Chin Lee Siew Li Teoh Source Type: research
Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression
Conclusions: Analysis showed zuranolone-treated patients with PPD experienced greater symptom improvement than SSRI-treated patients from Day 15 onward, with largest mean difference at Day 45. Adjusting for differences between placebo arms, zuranolone may be associated with greater PPD symptom improvement (measured by EPDS) vs. SSRIs.PMID:38523596 | DOI:10.1080/13696998.2024.2334160 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 25, 2024 Category: Health Management Authors: S Meltzer-Brody M E Gerbasi C Mak Y Toubouti S Smith N Roskell R Tan S Chen K M Deligiannidis Source Type: research
